Spinal Muscular Atrophy Treatment: The Mtor Regulatory Intervention Publisher Pubmed



Lashgari NA^{1, 2} ; Roudsari NM^{1, 2} ; Shayan M^{3, 4} ; Eshraghi S¹ ; Momtaz S^{2, 5, 6} ; Jamialahmadi T^{7, 8} ; Abdolghaffari AH^{1, 2} ; Sahebkar A^{8, 9, 10, 11} Show Affiliations
Source: Current Medicinal Chemistry Published:2024

Abstract

Spinal muscular atrophy (SMA) is a hereditary disorder affecting neurons and muscles, resulting in muscle weakness and atrophy. Most SMA cases are diagnosed during infancy or early childhood, the most common inherited cause of infant mortality without treatment. Still, SMA might appear at older ages with milder symptoms. SMA patients demonstrate progressive muscle waste, movement problems, tremors, dysphagia, bone and joint deformations, and breathing difficulties. The mammalian target of rapamycin (mTOR), the mechanistic target of rapamycin, is a member of the phosphatidyli nositol 3-kinase-related kinase family of protein kinases encoded by the mTOR gene in humans. The mTOR phosphorylation, deregulation, and autophagy have shown dissimilarity amongst SMA cell types. Therefore, exploring the underlying molecular process in SMA therapy could provide novel insights and pave the way for finding new treatment options. This paper provides new insight into the possible modulatory effect of mTOR/ autophagy in SMA management. © 2024 Bentham Science Publishers.